Free carnitine (C0) LOD ~0.01 uM, short-chain (C2-C5) ~0.02 uM, medium/long-chain ~0.03-0.05 uM
4.4 Limitations In terms of the data received in the FAERS database, it is a spontaneous reporting system, and involving reports submitted by different reporters introduce the potential for duplicate records and variable quality of information
Some exosome products claim impressive benefits in their marketing, but come with little published clinical data
Semaglutide does seem to have fewer side effects than Liraglutide in total (perhaps due to the fact that it is only injected once a week instead of daily), but the potency of Semaglutide may mean that these side effects could be more intense
As a result, tirzepatide prescriptions lead to higher weight loss totals, on average, more than semaglutide